The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.

IMiD 的分子基础诱导 CRL4CRBN 泛素 E3 连接酶招募新底物。

• 批准号: 9899745
• 负责人: Eric Sebastian Fischer
• 金额: $ 39.59万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-01 至 2022-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9899745
• 关键词: Address; Angiogenesis Inhibition; Binding; Biochemical; Biological Assay; Biology; Biophysics; Cell Line; Cells; Cellular Assay; Cellular biology; Chemicals; Clinical; Collaborations; Communities; Complex; Computer Models; Crystallization; Data; Data Set; Development; Dysmyelopoietic Syndromes; Erythema; Exhibits; FDA approved; Failure; Flow Cytometry; Flowcharts; Future; HCT116 Cells; Hematologic Neoplasms; Immune system; In Vitro; Individual; Interleukin-2; Libraries; Ligase; Link; Literature; Lymphoid; Mass Spectrum Analysis; Medicine; Modification; Molecular; Molecular Structure; Multiple Myeloma; Mutation Analysis; NF-kappa B; Outcome; Oxidative Stress Induction; Pharmaceutical Preparations; Physiologic pulse; Production; Property; Proteins; Proteomics; Publishing; RBX1 gene; Resources; Seminal; Signal Transduction; Specificity; Spectrometry; Structure; Substrate Specificity; System; TNF gene; Teratogens; Testing; Thalidomide; Therapeutic; Time; Ubiquitin; Ubiquitination; Validation; Western Blotting; Work; X-Ray Crystallography; Zinc Fingers; analog; base; biophysical properties; casein kinase I; chromosome 5q loss; cytokine; drug discovery; drug mechanism; effective therapy; experimental study; falls; gain of function; insight; interest; lenalidomide; molecular mechanics; multicatalytic endopeptidase complex; novel; novel therapeutics; pomalidomide; prevent; protein degradation; receptor; reconstitution; recruit; response; small molecule; structural biology; therapeutic target; tool; transcription factor; ubiquitin ligase; ubiquitin-protein ligase

Thalidomide and its analogs lenalidomide and pomalidomide (IMiDs), are highly effective treatments for hematologic malignancies such as multiple myeloma (MM) or del(5q) myelodysplastic syndrome (5q-MDS), as well as an FDA approved treatment for erythema nodosom leprosum (ENL). Over decades IMiDs were found to have broad but not necessary related effects, ranging from induction of oxidative stress, inhibition of angiogenesis, to multiple effects on the immune system such as enhanced production of cytokine interleukin-2 (IL-2) and inhibition of cytokine tumor necrosis factor (TNF). A seminal breakthrough in understanding the activity of IMiDs was the discovery that IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1- CRBN (CRL4CRBN) E3 ubiquitin ligase, and to exhibit dual activity: 1) preventing CRL4CRBN from ubiquitinating its native substrates, including MEIS2, and 2) to alter the specificity of the CRL4CRBN ubiquitin ligase to ubiquitinate new targets, notably the lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), and casein kinase 1 alpha (CK1α). Therefore IMiDs impart gain-of-function properties to the CRL4CRBN substrate receptor that enable binding and ubiquitination of key therapeutic targets. While IKZF1/3 and Ck1α provide a plausible explanation for IMiD efficacy, they fall short in explaining all of the cellular and clinical response induced by IMiDs and other substrates likely exist. Moreover, the finding that IMiDs act by altering the substrate repertoire of the CRL4CRBN ubiquitin ligase towards neo-substrates has transformative potential to drug discovery; however, we do not understand the molecular basis of neo-substrate recruitment. Important unresolved issues are 1) the complete substrate repertoire of IMiDs, 2) the structural features of the degron recognized by a CRL4CRBN-IMiD complex, and 3) how on molecular grounds, modifications to IMiDs can confer substrate selectivity. In Aim 1 we will validate a list of high-confidence substrate candidates generated with a novel pulse-SILAC mass spectrometry approach. We will publish validated substrates as a resource to the community, which will greatly facilitate the in-depth understanding of the clinical and cellular outcomes of IMiD treatment. In Aim 2, we will use a combination of X-ray crystallography, biochemical reconstitutions and cellular experiments to address the molecular basis of IMiD activity. In depth understanding of this novel drug mechanism will guide development of future medicine. Leveraging our intricate molecular and structural understanding, we will develop IMiD derivatives with altered substrate selectivity in Aim 3 of this proposal. Through a set of quantitative assays developed in the lab, we are for the first time able to follow a structure and mechanism guided approach to synthesize derivatives of IMiDs and explain how subtle chemical modifications result in altered substrate specificity. Taken together, we will define the molecular framework that underlies IMiD induced ligase repurposing.

沙利度胺及其类似物来那度胺和泊马度胺（IMiD）是高度有效的治疗药物， 血液恶性肿瘤，如多发性骨髓瘤（MM）或del（5 q）骨髓增生异常综合征（5 q-MDS）， 以及FDA批准的用于麻风结节性红斑（ENL）的治疗。几十年来， 具有广泛但不必要的相关作用，包括诱导氧化应激，抑制 血管生成，对免疫系统的多种影响，如细胞因子白细胞介素-2的产生增加 （IL-2）和细胞因子肿瘤坏死因子（TNF）的抑制。在理解 IMiDs的活性是发现IMiDs结合CRBN，CRBN是CUL 4-RBX 1-DDB 1-CUL 4的底物受体。 CRBN（CRL 4CRBN）E3泛素连接酶，并表现出双重活性：1）防止CRL 4CRBN泛素化 其天然底物，包括MEIS 2，和2）改变CRL 4CRBN泛素连接酶的特异性， 泛素化新靶点，特别是淋巴转录因子Ikaros（IKZF 1）和Aiolos（IKZF 3）， 酪蛋白激酶1 α（CK 1 α）。因此，IMiD赋予CRL 4CRBN基底功能增益特性 受体，能够结合和泛素化的关键治疗目标。而IKZF 1/3和Ck 1 α提供了一种 IMiD疗效的合理解释，但它们无法解释所有的细胞和临床反应 IMiD和其他底物诱导的可能存在。此外，IMiDs通过改变 CRL 4CRBN泛素连接酶对新底物的底物库具有转化潜力， 药物发现;然而，我们不了解新底物募集的分子基础。重要 未解决的问题是1）IMiDs的完整底物库，2）降解决定子的结构特征 由CRL 4CRBN-IMiD复合物识别，以及3）在分子基础上，对IMiD的修饰如何赋予 底物选择性在目标1中，我们将验证使用 新型脉冲SILAC质谱法。我们将发布经验证的底物作为资源， 这将极大地促进对IMiD临床和细胞结局的深入了解 治疗在目标2中，我们将结合使用X射线晶体学、生化重组和 细胞实验，以解决IMiD活性的分子基础。深入了解这种新药 机制将指导未来医学的发展。利用我们复杂的分子和结构 理解，我们将在本提案的目标3中开发具有改变的底物选择性的IMiD衍生物。 通过实验室开发的一套定量分析，我们首次能够跟踪结构， 机制指导的方法来合成IMiDs的衍生物，并解释如何微妙的化学修饰 导致底物特异性改变。综合起来，我们将定义构成 IMiD诱导连接酶再利用。